Navigation Links
Molecule identified that increases survival of stomach cancer patients
Date:9/14/2010

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jess Garca-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

Pharmacogenetics studies the genetic bases determining the response of an individual to treatment, as well as possible toxic reactions; pharmacogenomics analyses the molecular and biological mechanisms involved in a disease in order to develop new medicines. "We know that variations in small molecules (microRNAs) give rise to different responses to the same pharmaceutical drug. In this line, a number of approaches are being made in clinical practice, such as the study of mutations of the K-RAS gene in cancer of the colon or of the EGFR in lung cancer, and which enable directing individualised treatment for each patient".

The study presented at this scientific meeting analysed the role of microRNA 451 in stomach cancer, "Patients with a high expression of this molecule show greater survival rates, and so could be a biomarker for treatment response". The CIMA researchers are also taking part in other trials, such as studies with the 192 and 215 microRNAs, which influence the response to pharmaceutical drugs against cancer of the colon, at the preclinical phase.

Psychiatric and cardiovascular diseases

Besides its application in cancer, pharmacogenetics is demonstrating its efficacy in other disciplines such as psychiatry. So today, more individualised treatment can be determined for psychotic disorders and epilepsy for each patient.

Another field that is growing fast is that involving the treatment of cardiovascular diseases. "One of the great risks of these illnesses is controlling the thrombotic processes involved in cerebrovascular accidents. The study of certain genes, such as ALOX5AP, can direct the most appropriate medication for each patient", explained Dr. Garca-Foncillas.

In the opinion of the CIMA researcher, "the convergence of genetic and pharmacological studies has created a way for optimising both the treatment for each patient as well as health resources, given that we will be able to use pharmaceutical drugs in suitable doses, with fewer side effects and with patients that show better therapeutic response".


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
0034-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. Scientists identify molecules involved in touch and other mechanically activated systems
2. Juelich researchers take a look inside molecules
3. Molecules delivering drugs as they walk
4. One molecule, many more insulin-producing cells to treat diabetes, says Pitt team
5. Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells
6. Correcting a trick of the light brings molecules into view
7. Molecules typically found in blue jean and ink dyes may lead to more efficient solar cells
8. Stretching molecules yields new understanding of electricity
9. Single-molecule manipulation for the masses
10. Scripps research scientists determine structure of immune molecule that counteracts HIV strains
11. New bacterial signaling molecule could lead to improved vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... VIEW, Calif. , Feb. 2, 2016 /PRNewswire/ ... retinopathy market, Frost & Sullivan recognizes US-based Intelligent ... America Frost & Sullivan Award for New Product ... provider in North America , ... in the rapidly growing diabetic retinopathy market. The ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... WARRINGTON, Pa. , Feb. 3, 2016 /PRNewswire/ ... biotechnology company focused on developing aerosolized KL4 surfactant ... Board of Directors has approved an inducement award ... Craig Fraser , its newly appointed President and ... the Board,s Compensation Committee on February 1, 2016 ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered organ ... and bronchus, today announced that CEO Jim ... CEO & Investor Conference on Tuesday, February ... New York City . HART,s presentation ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... validating a series of potential targets (epitopes) specific to misfolded, propagating strains of ... to create specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from the ...
Breaking Biology Technology: